Outcomes of Segmentectomy With or Without Preoperative Biopsy in Non-Small Cell Lung Cancer (NSCLC)
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2025.02.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Sneha S Alaparthi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Thomas Jefferson University Hospital, Department of Surgery, Division of Esophageal and Thoracic Surgery, Philadelphia, PA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonectomy, Preoperative Care. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Bristol Myers Squibb Foundation.
Abstract (Originalsprache)
BACKGROUND: There is a discussion amongst oncologic societies regarding the necessity of preoperative biopsy prior to resection in lung cancer. We aim to examine outcomes of segmentectomy with or without preoperative biopsy in non-small cell lung cancer (NSCLC) patients. METHODS: A retrospective cohort study was conducted utilizing the National Cancer Database. Adult patients diagnosed with clinical stage I (N0 M0, tumor size ≤ 2 cm) NSCLC between 2010 and 2019 who underwent segmentectomy were included. Patients with carcinoid tumors or who received neoadjuvant systemic or radiation therapy were excluded. Demographic and clinical variables were analyzed. Propensity score matching (PSM) was performed to adjust for confounders between patients who underwent segmentectomy with versus without preoperative biopsy. Short term outcomes (readmission, 30-day and 90-day survival) and long-term overall survival (OS) were compared between groups. RESULTS: In total, 6891 patients met inclusion criteria, of which 2287 (33.2%) underwent preoperative biopsy and 4604 (66.8%) did not. There was no significant difference in 30-day readmission (P = .13), 30-day survival (P = .26), and 90-day survival (P = .31). Patients who did not receive preoperative biopsy was associated with a higher 5-year OS (P = .02); however, post-PSM, there was no significant difference between the 2 groups (P = .20). CONCLUSIONS: After PSM, no significant difference was found in margin positivity, nodal upstaging, 30-day readmission, 30- and 90-day survival, and 5-year OS between cohorts. This demonstrates that segmentectomy without preoperative biopsy remains a safe option for those with early stage, ≤ 2 cm NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Thomas Jefferson University Hospital, Department of Surgery, Division of Esophageal and Thoracic Surgery, Philadelphia, PA.
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
- Thomas Jefferson University Hospital, Department of Surgery, Division of Esophageal and Thoracic Surgery, Philadelphia, PA. Electronic address: Olugbenga.Okusanya@jefferson.edu.
Förderung
- Bristol Myers Squibb Foundation
Zitieren
APA
Alaparthi, S. S., Ho, A., Rshaidat, H., Whitehorn, G., Madeka, I., Ishwar, A., Grenda, T., Jacob, J. D., Evans, N. R., & Okusanya, O. T. (2025). Outcomes of Segmentectomy With or Without Preoperative Biopsy in Non-Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.02.004
Vancouver
Alaparthi SS, Ho A, Rshaidat H, Whitehorn G, Madeka I, Ishwar A, et al. Outcomes of Segmentectomy With or Without Preoperative Biopsy in Non-Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.02.004
BibTeX
@article{Alaparthi2025,
author = {Alaparthi, Sneha S and Ho, Annie and Rshaidat, Hamza and Whitehorn, Gregory and Madeka, Isheeta and Ishwar, Anurag and Grenda, Tyler and Jacob, John D and Evans, Nathaniel R and Okusanya, Olugbenga T},
title = {Outcomes of Segmentectomy With or Without Preoperative Biopsy in Non-Small Cell Lung Cancer (NSCLC)},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2025.02.004}
}
EUVIMED